Dose Proportionality of Fentanyl Buccal Tablet in Doses Ranging from 600 to 1300μg in Healthy Adult Subjects

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Drug Investigation

• Publication date

  2012-08-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF03256906
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Fentanyl buccal tablet for the treatment of breakthrough pain in opioid‐tolerant patients with chronic cancer pain

  2009cited by this paper
• Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.

  2007cited by this paper
• Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study*

  2007cited by this paper
• Absolute and Relative Bioavailability of Fentanyl Buccal Tablet and Oral Transmucosal Fentanyl Citrate

  2007cited by this paper
• Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.

  2007cited by this paper
• Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.

  2006cited by this paper
• Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.

  2006cited by this paper
• Fentanyl effervescent buccal tablets

  2006cited by this paper
• A Randomized, Placebo-controlled Study of Fentanyl Buccal Tablet for Breakthrough Pain in Opioid-treated Patients With Cancer

  2006cited by this paper
• Breakthrough pain in malignant and non‐malignant diseases: a review of prevalence, characteristics and mechanisms

  2005cited by this paper
• Pharmacokinetics and Dose Proportionality of Fentanyl Effervescent Buccal Tablets in Healthy Volunteers

  2005cited by this paper
• Confidence Interval Criteria for Assessment of Dose Proportionality

  2004cited by this paper
• Breakthrough pain: definition, prevalence and characteristics

  1990cited by this paper
• Clinical Pharmacokinetics of Cyclosporin

  1986cited by this paper
• The uptake of fentanyl by erythrocytes

  1982cited by this paper

• Sampling site has a critical impact on PBPK modeling

  2019influential citation
• Sampling Site Has a Critical Impact on Physiologically Based Pharmacokinetic Modeling

  2019cites this paper
• Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis

  2017cites this paper
• Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care

  2015cites this paper
• Medications for Cancer Breakthrough Pain

  2013cites this paper
• Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses

  2012cites this paper
• Pharmacokinetics of Fentanyl Buccal Tablet: A Pooled Analysis and Review

  2012cites this paper
• A review of the pharmacokinetic profile of transmucosal fentanyl formulations

  2012cites this paper
• A Comprehensive Review of Rapid-Onset Opioids for Breakthrough Pain

  2012cites this paper
• Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.

  2011cites this paper